Here, we demonstrate that LeY expression is detected in both adenocarcinoma and neuroendocrine prostate cancer, and is independent of AR or PSMA, and thus LeY CAR T cells could be applicable for the treatment of a diverse range of prostate tumors. This evidence concerns the gene FOLH1 and adenocarcinoma.